Allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: Meta-analysis of randomized controlled trials

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 431-437

  Zhang, Haoran ^a   Chen, Junmin ^a   Que, Wenzhong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Allogeneic; Bone marrow; Meta analysis; Peripheral blood stem cell; Transplantation

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER RELAPSE; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INFECTION; META ANALYSIS; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; TREATMENT OUTCOME; VEIN OCCLUSION;

BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84857231736     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.10.016     Document Type: Article

References (37)

1. Gratwohl A., Passweg J., Baldomero H., Urbano-Ispizua A. Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 2001, 27:899-916.
2. Koh L.P., Chao N.J. Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review. Blood Cells Mol Dis 2008, 40:20-24.
3. Gratwohl A., Baldomero H., Horisberger B., Schmid C., Passweg J., Urbano-Ispizua A. Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002, 100:2374-2386.
4. Champlin R.E., Schmitz N., Horowitz M.M., Chapuis B., Chopra R., Cornelissen J.J., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000, 95:3702-3709.
5. Storek J., Dawson M.A., Storer B., Stevens-Ayers T., Maloney D.G., Marr K.A., et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001, 97:3380-3389.
6. Cutler C., Giri S., Jeyapalan S., Paniagua D., Viswanathan A., Antin J.H. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001, 19:3685-3691.
7. Stem Cell Trialists' Collaborative Group Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087.
8. Horan J.T., Liesveld J.L., Fernandez I.D., Lyman G.H., Phillips G.L., Lerner N.B., et al. Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. Bone Marrow Transplant 2003, 32:293-298.
9. Ram R., Gafter-Gvili A., Shpilberg O., Raanani P. Allogeneic hematopoietic cell transplantation for adult patients with acute leukemia: the role of meta-analyses. Acta Haematol 2011, 125:39-46.
10. Korbling M., Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood 2001, 98:2900-2908.
11. Bensinger W.I., Clift R., Martin P., Appelbaum F.R., Demirer T., Gooley T., et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996, 88:2794-2800.
12. Bensinger W.I., Deeg H.J. Blood or marrow? (Commentary). Lancet 2000, 355:1199-1200.
13. Higgins J.P.T., Deeks J.J., Altman DG Special topics in statistics. Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009] 2009, The Cochrane Collaboration, Available from www.cochrane-handbook.org (chapter 16).
14. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
15. Bensinger W.I., Martin P.J., Storer B., Clift R., Forman S.J., Negrin R., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
16. Schmitz N., Beksac M., Hasenclever D., Bacigalupo A., Ruutu T., Nagler A., et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002, 100:761-767.
17. Powles R., Mehta J., Kulkarni S., Treleaven J., Millar B., Marsden J., et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000, 355:1231-1237.
18. Blaise D., Kuentz M., Fortanier C., Bourhis J.H., Milpied N., Sutton L., et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000, 18:537-546.
19. Vigorito A.C., Marques Júnior J.F., Aranha F.J., Oliveira G.B., Miranda E.C., De Souza C.A. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: an update. Haematologica 2001, 86:665-666.
20. Couban S., Simpson D.R., Barnett M.J., Bredeson C., Hubesch L., Howson-Jan K., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002, 100:1525-1531.
21. Heldal D., Tjønnfjord G., Brinch L., Albrechtsen D., Egeland T., Steen R., et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000, 25:1129-1136.
22. Oehler V.G., Radich J.P., Storer B., Blume K.G., Chauncey T., Clift R., et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005, 11:85-92.
23. Cornelissen J.J., van der Holt B., Petersen E.J., Vindelov L., Russel C.A., Höglund M., et al. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol 2003, 31:855-864.
24. Morton J., Hutchins C., Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001, 98:3186-3191.
25. Afessa B., Peters S.G. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med 2006, 27:297-309.
26. Smith L.A., Wright-Kanuth M.S. Complications and risks in hematopoietic stem cell transplant patients. Clin Lab Sci 2001, 14:118-124.
27. Junghanss C., Marr K.A. Infectious risks and outcomes after stem cell transplantation: are non-myeloablative transplants changing the picture?. Curr Opin Infect Dis 2002, 15:347-353.
28. Bensinger W.I., Weaver C.H., Appelbaum F.R., Rowley S., Demirer T., Sanders J., et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995, 85:1655-1658.
29. Petiti D.B. Meta-analysis decision analysis and cost-effectiveness analysis: methods for quantitative synthesis in medicine 2000, Oxford Press, New York, NY. 2nd ed.
30. Schattenberg A.V., Dolstra H. Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Curr Opin Oncol 2005, 17:617-621.
31. Basara N., Baurmann H., Kolbe K., Yaman A., Labopin M., Burchardt A., et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005, 35:1011-1018.
32. Arpinati M., Green C.L., Heimfeld S., Heuser J.E., Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000, 95:2484-2490.
33. Pan L., Delmonte J., Jalonen C.K., Ferrara J.L. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995, 86:4422-4429.
34. Elmaagacli A.H., Beelen D.W., Opalka B., Seeber S., Schaefer U.W. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 1999, 94:384-389.
35. Bensinger W. Stem Cell Trialists' Collaborative Group. Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrowtransplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant 2006, 38:539-546.
36. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
37. Peggs K., Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003, 348:1048-1050.